{"nctId":"NCT00075218","briefTitle":"A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)","startDateStruct":{"date":"2003-12"},"conditions":["Gastrointestinal Stromal Tumor"],"count":361,"armGroups":[{"label":"B","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"A","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: SU011248"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"SU011248","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent\n* Failed Gleevec treatment or intolerant to Gleevec therapy\n\nKey Exclusion Criteria:\n\n* Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase","description":"Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.3","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"Time from randomization to first documentation of objective tumor progression or to death due to any cause (on treatment or within 28 days of last dose).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.9","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Status of Subjects","description":"Number of subjects alive at end of study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"176","spread":null},{"groupId":"OG001","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Time from date of randomization to date of death due to any cause.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival Based on the Rank Preserving Structural Failure Time Method","description":"time from date of randomization to date of death due to any cause (rank preserving structural failure time method).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null},{"groupId":"OG001","value":"39.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Best Overall Tumor Response During Double-blind Treatment Phase","description":"Tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"128","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Confirmed Objective Response (CR or PR) in Subjects","description":"Overall confirmed objective response = confirmed Complete Response (CR) OR confirmed Partial Response (PR) according to RECIST. Confirmed responses were those that persisted on repeat imaging study â‰¥ 4 weeks after initial documentation of response.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Tumor Response (TTR)","description":"Time from date of randomization to first documentation of objective tumor response that was subsequently confirmed. TTR was only calculated for the subgroup of subjects with a confirmed objective tumor response.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Performance Status Maintenance","description":"Time from randomization until the last time the performance status was no worse than at baseline or to death due to cancer in the absence of previous documentation of performance status worsening.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Tumor Progression (TTP) as Assessed in the Double-blind Treatment Phase at End of Study","description":"Time from randomization to first documentation of objective tumor progression based on the assessment of an independent, third-party imaging laboratory using RECIST (Response Evaluation Criteria in Solid Tumors).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.6","spread":null},{"groupId":"OG001","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Progression Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)","description":"25th Quartile: Time to Progression. Progression: a) No change (NC) in MPQ-PPI score (0=no pain to 5=excruciating pain) with increase total analgesic use \\>= 50% over baseline OR b) Increase score \\>= 1 point with either NC in total analgesic use or increase total analgesic use \\>= 50% over baseline. (50th Quartile not achieved.)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects With Pain Relief Response Using McGill Pain Questionnaire-present Pain Intensity (MPQ-PPI)","description":"MPQ-PPI: 0=no pain to 5= excruciating pain. Pain Relief Response= 1) Decrease by \\>= 1 points in MPQ-PPI score with either Decrease or No Change in total analgesic use \\>= 50% over baseline OR 2) No change in MPQ-PPI score with Decrease total analgesic use \\>= 50% over baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline Score in EuroQoL Visual Analog Scale (EQ-VAS)","description":"Change: median score at observation minus median score at baseline. EQ-VAS score on the self-rated \"thermometer,\" indicating the patient's own assessment of their health status from 0 (worst) to 100 (best) imaginable health state.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0","spread":null},{"groupId":"OG001","value":"-1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D Health State Profile Index","description":"Change: median index score at observation minus median index score at baseline. EQ-5D is a generic instrument that describes health status in 5 dimensions (mobility, self-care, pain/discomfort, anxiety/depression, usual activities) with a weighted health Index based on general population values where where 0.0 = death and 1.0 = perfect health.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.017","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.036","spread":null},{"groupId":"OG001","value":"0.000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":null},{"groupId":"OG001","value":"0.059","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":83},"commonTop":["Fatigue","Diarrhoea","Abdominal pain","Nausea","Anorexia"]}}}